CSIMarket Company Name, Ticker, Customers, else..
 
Reshape Lifesciences Inc   (NASDAQ: RSLS)
Other Ticker:  
 
 
Price: $4.5200 $-0.15 -3.212%
Day's High: $4.859 Week Perf: -9.6 %
Day's Low: $ 4.52 30 Day Perf: -1.09 %
Volume (M): 22 52 Wk High: $ 29.00
Volume (M$): $ 98 52 Wk Avg: $8.97
Open: $4.80 52 Wk Low: $4.09



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 1
 Employees 41
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Reshape Lifesciences Inc
Reshape Lifesciences Inc is a medical technology company that focuses on developing and commercializing innovative medical devices to treat obesity and metabolic diseases. Their main product is the ReShape' Integrated Dual Balloon System, which is designed to aid in weight loss by occupying space in the stomach and making patients feel full. The company aims to provide non-surgical solutions for patients struggling with obesity, offering an alternative to traditional weight loss methods. In addition to their primary product, Reshape Lifesciences Inc also offers related services such as patient support programs and physician training to ensure successful patient outcomes.


   Company Address: 18 Technology Dr, Suite 110 Irvine 92618 CA
   Company Phone Number: 429-6680   Stock Exchange / Ticker: NASDAQ RSLS


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
JNJ        1.77% 
BDX        0.5% 
BSX        4.28% 
CNMD   -2.6%    
HOLX   -0.8%    
ISRG        9.8% 
• View Complete Report
   



Merger and Acquisition

ReShape Lifesciences Sets the Stage for Growth with Vyome Therapeutics Merger and Biorad Medisys Acquisition Amidst Groundbreaking Health Canada Approval,

Published Mon, Jan 13 2025 1:31 PM UTC

Transactions Continue to Progress and Remain on Track Following ReShape Lifesciences Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research CollaborationsIn an era where health priorities are undergoing significant shifts, ReShape Lifesciences, a frontrunner in weight loss solutions and diabetes management, has ma...
Management Announcement

ReShape Lifesciences Pioneers Innovative Approaches in Weight Loss and Diabetes Management with New Health Canada Approval and Strategic Research Collaborations

Published Tue, Nov 12 2024 1:31 PM UTC

In a remarkable leap forward for obesity management and diabetes treatment, ReShape Lifesciences has recently garnered Health Canada?s approval for its next-generation Lap-Band 2.0, equipped with the innovative FLEX Technology. Designed with the patient s experience at the forefront, this advanced device promises to enhance safety, comfort, and efficacy during weight-loss pr...
Product Service News

Collaborating for a Cure ReShape Lifesciences and USC?s CARSS Innovate Next-Gen Diabetes Treatment,

Published Mon, Nov 11 2024 1:31 PM UTC

Unveiling the Future of Diabetes Management: ReShape Lifesciences and USC s CARSS Invest in Groundbreaking Neuromodulation Technology In an exciting development for the diabetes treatment landscape, ReShape Lifesciences, a pioneer in weight-loss solutions, has announced a strategic collaboration with the University of Southern California s Center for Autonomic Nerve Recordin...
Shares

ReShape Lifesciences and Vyome Therapeutics Merger Set to Transform Shareholder Landscape Amidst Promising Market Movements

Published Thu, Sep 19 2024 12:31 PM UTC

In a significant development for investors and stakeholders, ReShape Lifesciences Inc. has announced that its merger with Vyome Therapeutics will officially take effect at the commencement of trading on September 23, 2024. This landmark merger comes on the heels of a prior announcement made on July 9, 2024, where both companies articulated their intent to join forces in an e...
Contract

ReShape Lifesciences and Vyome Therapeutics Announce Merger Agreement to Advance Treatment for Immuno-Inflammat...

Published Tue, Jul 9 2024 12:31 PM UTC

In an exciting development within the pharmaceutical industry, ReShape Lifesciences has announced the signing of a definitive merger agreement with Vyome Therapeutics, a clinical stage specialty pharmaceutical company focused on tackling immuno-inflammatory diseases with unmet medical need. This significant merger aims to bring forth groundbreaking treatment options for pati...






Reshape Lifesciences Inc's Segments
United States    87.65 % of total Revenue
Australia    4.84 % of total Revenue
Europe    7.33 % of total Revenue
Rest of World    0.17 % of total Revenue





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com